– Study met primary endpoint demonstrating cebranopadol is significantly less abusable than oxycodone when taken intranasally (i.e., snorted) with majority of patients indicating no desire to take ...
Having shown last week that its opioid alternative can reduce post-surgery pain, Tris Pharma is back with another slice of clinical data to show that the drug is less likely to be abused. The phase 1 ...
Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced that the company will present intranasal human abusability data from cebranopadol, an investigational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results